Ravasio, R., Viti, R. and Roscini, A.S. 2023. Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy. AboutOpen. 10, 1 (Jan. 2023), 13–21. DOI:https://doi.org/10.33393/ao.2023.2515.